MicrobiotiX Co., Ltd
Microbiotix, Inc. is a clinical stage biopharmaceutical company dedicated to discovering and developing proprietary small molecule drugs targeting serious infectious diseases, including multi-drug resistant pathogens. The company has a strong focus on innovation, with a history of NIH awards, and is advancing several programs including MBX-400 for cytomegalovirus and antibacterial programs targeting multidrug-resistant bacteria. Microbiotix collaborates with partners like CARB-X and the UK’s AMR Centre, and maintains a robust pipeline of novel therapeutics aimed at combating antimicrobial resistance.
Industries
Nr. of Employees
small (1-50)
MicrobiotiX Co., Ltd
Patents
Metabolically stable N-acylaminooxadiazoles useful as antibacterial agents
US-11505533-B2
View Details
Metabolically stable N-acylaminooxadiazoles useful as antibacterial agents
US-11505533-B2
View DetailsProducts
Oral nucleoside-analog antiviral candidate for CMV and ocular viruses (completed Phase 1)
A small-molecule nucleoside analog antiviral with dual DNA polymerase and kinase inhibitory activity, demonstrated in vitro potency, activity versus resistant isolates, no genotoxicity reported, and completion of Phase 1 clinical testing. Also evaluated for adenoviral conjunctivitis and other ocular viral indications in preclinical studies.
Spectinomycin-derivative antibacterial series for TB (spectinamides)
Semisynthetic spectinomycin analogs optimized for narrow-spectrum antitubercular activity with demonstrated in vitro potency, lack of cross-resistance to standard TB agents, and efficacy in multiple in vivo TB models.
Aminospectinomycins for drug-resistant gonorrhea and other pathogens
Novel spectinomycin-derived compounds with improved potency against Gram-negative and Gram-positive species, including activity versus drug-resistant Neisseria gonorrhoeae and efficacy in in vivo models.
Type III secretion system inhibitor program (Pseudomonas antivirulence)
Small-molecule inhibitors targeting the Type III secretion system of Pseudomonas aeruginosa to block toxin delivery, reverse disruption of host innate immunity, and reduce establishment and dissemination of infection.
Pyranopyridine efflux pump inhibitor program (RND pumps)
Development of pyranopyridine-derived inhibitors of RND-type efflux pumps intended for use as adjunctive therapy to increase antibiotic potency and reduce resistance frequency in Enterobacteriaceae and other Gram-negative pathogens.
Oral nucleoside-analog antiviral candidate for CMV and ocular viruses (completed Phase 1)
A small-molecule nucleoside analog antiviral with dual DNA polymerase and kinase inhibitory activity, demonstrated in vitro potency, activity versus resistant isolates, no genotoxicity reported, and completion of Phase 1 clinical testing. Also evaluated for adenoviral conjunctivitis and other ocular viral indications in preclinical studies.
Spectinomycin-derivative antibacterial series for TB (spectinamides)
Semisynthetic spectinomycin analogs optimized for narrow-spectrum antitubercular activity with demonstrated in vitro potency, lack of cross-resistance to standard TB agents, and efficacy in multiple in vivo TB models.
Aminospectinomycins for drug-resistant gonorrhea and other pathogens
Novel spectinomycin-derived compounds with improved potency against Gram-negative and Gram-positive species, including activity versus drug-resistant Neisseria gonorrhoeae and efficacy in in vivo models.
Type III secretion system inhibitor program (Pseudomonas antivirulence)
Small-molecule inhibitors targeting the Type III secretion system of Pseudomonas aeruginosa to block toxin delivery, reverse disruption of host innate immunity, and reduce establishment and dissemination of infection.
Pyranopyridine efflux pump inhibitor program (RND pumps)
Development of pyranopyridine-derived inhibitors of RND-type efflux pumps intended for use as adjunctive therapy to increase antibiotic potency and reduce resistance frequency in Enterobacteriaceae and other Gram-negative pathogens.
Services
Collaborative arrangements with public and private partners to advance discovery and development of anti-infective therapeutics, including co-development and grant-funded projects.
Collaborative arrangements with public and private partners to advance discovery and development of anti-infective therapeutics, including co-development and grant-funded projects.
Expertise Areas
- Antiviral therapeutics development
- Antibiotic discovery for multidrug-resistant pathogens
- Preclinical pharmacology and in vivo infection models
- Medicinal chemistry and SAR
Key Technologies
- Small-molecule medicinal chemistry
- Nucleoside-analog antiviral chemistry
- In vitro virology assays
- In vitro antibacterial assays (including efflux and trans-translation assays)
News & Updates
View Upcoming Events
There are no upcoming events at this time.
Top recipient of NIH awards among Massachusetts biotech/pharma companies (2013-2020)
Microbiotix has consistently been the top recipient of NIH awards among Massachusetts biotech/pharma companies from 2013 to 2020.
View Upcoming Events
There are no upcoming events at this time.
Top recipient of NIH awards among Massachusetts biotech/pharma companies (2013-2020)
Microbiotix has consistently been the top recipient of NIH awards among Massachusetts biotech/pharma companies from 2013 to 2020.